Kessler Topaz Meltzer & Check joined earlier legal scrutiny after Celcuity said its FDA-approved breast cancer therapy Revtorpyk is expected to launch commercially in late Q3 2026.
Celcuity Inc. is facing multiple investor-law-firm probes after its shares fell sharply following the company’s July 14, 2026 announcement that the U.S. Food and Drug Administration approved its breast cancer therapy Revtorpyk (gedatolisib) and that it anticipates a commercial launch in late Q3 2026. That launch timing came in later than some analysts expected. Stifel analyst Stephen Wiley said the “late 3Q26 launch guidance seems somewhat extended,” while Leerink analyst Andrew Berens said approval was largely expected but that he “did not anticipate [a Q3 launch date] given prior commentary on launch readiness.” Celcuity shares fell $19.54, or 17.6%, to close at $91.51 on July 15, 2026. Pomerantz LLP had already disclosed an investigation, and Kessler Topaz Meltzer & Check, LLP said it is also investigating potential violations of the federal securities laws on behalf of investors who purchased or acquired Celcuity securities and suffered losses.